<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937675</url>
  </required_header>
  <id_info>
    <org_study_id>eFT508-0002</org_study_id>
    <nct_id>NCT02937675</nct_id>
  </id_info>
  <brief_title>A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies</brief_title>
  <official_title>A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Effector Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Effector Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and
      cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and
      antitumor activity of Tomivosertib (eFT-508). The study will evaluate oral daily
      administration of Tomivosertib (eFT-508). Treatment and study subject evaluation will be
      performed in 21-day cycles.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    patient recruitment
  </why_stopped>
  <start_date type="Actual">February 8, 2017</start_date>
  <completion_date type="Actual">April 4, 2019</completion_date>
  <primary_completion_date type="Actual">November 12, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose and/or Recommended Dose within the tested Tomivosertib (eFT-508) dose range</measure>
    <time_frame>up to one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>up to three years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tomivosertib (eFT-508) Escalation Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This portion of the study will evaluate the safety and pharmacology of a range of Tomivosertib (eFT-508) doses administered daily in subjects with previously treated lymphomas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tomivosertib (eFT-508) Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This portion of the study provides cohort expansion to further explore the safety, pharmacology, and clinical activity of a single dose level of Tomivosertib (eFT-508) monotherapy in subjects with specific previously treated lymphomas</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tomivosertib (eFT-508)</intervention_name>
    <description>eFT508</description>
    <arm_group_label>Tomivosertib (eFT-508) Escalation Cohort</arm_group_label>
    <arm_group_label>Tomivosertib (eFT-508) Expansion Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          2. Presence of an active hematological malignancy.

          3. Presence of measurable disease.

          4. Hematological malignancy has been previously treated, has relapsed after or progressed
             during prior therapy, and has limited potential for benefit from currently available
             therapy including hematopoietic stem cell transplantation.

          5. At least 2 weeks post any treatments/therapies at the time of first dose.

          6. Adequate bone marrow function.

          7. Adequate hepatic function.

          8. Adequate renal function.

          9. Normal coagulation panel.

         10. Negative antiviral serology.

         11. Willingness to use effective contraception.

        Exclusion Criteria:

          1. Central nervous system malignancy

          2. Gastrointestinal disease

          3. Significant cardiovascular disease

          4. Significant ECG abnormalities.

          5. Ongoing risk for bleeding due to active peptic ulcer disease, bleeding diathesis or
             requirement for systemic anticoagulation

          6. Ongoing systemic bacterial, fungal, or viral infection (including upper respiratory
             tract infections)

          7. Pregnancy or breastfeeding.

          8. Major surgery within 4 weeks before the start of study therapy.

          9. Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids

         10. Use of drugs that could prolong the QT interval within 7 days before the start of
             study therapy.

         11. Use of drugs that might pose a risk of a drug-drug interaction within 2-7 days before
             the start of study therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Barton, MD</last_name>
    <role>Study Director</role>
    <affiliation>CMO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samuel Oschin comprehensive Cancer Institute at Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>small molecule inhibitor of protein translation</keyword>
  <keyword>immunomodulator</keyword>
  <keyword>phase 1 dose escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

